Rheumatology 2014;53:21672174 doi:10.1093/rheumatology/ket487 Advance Access publication 8 February 2014
Original article Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia Roy Fleischmann1, Bradley Kerr2, Li-Tain Yeh3, Matt Suster4, Zancong Shen3, Elizabeth Polvent2, Vijay Hingorani2, Barry Quart4, Kimberly Manhard5, Jeffrey N. Miner6 and Scott Baumgartner4, on behalf of the RDEA594-111 Study Group Abstract Objective. The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout.
Results. Initial treatment with febuxostat 40 or 80 mg/day monotherapy resulted in 67% and 56% of subjects, respectively, achieving a sUA level
